Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-invasive Bladder Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 143 Lung Neoplasms 68 Carcinoma, Hepatocellular 57 Small Cell Lung Carcinoma 50 Breast Neoplasms 43 Squamous Cell Carcinoma of Head and Neck 32 Urinary Bladder Neoplasms 30 Biliary Tract Neoplasms 29 Colorectal Neoplasms 26 Cholangiocarcinoma 26 Triple Negative Breast Neoplasms 23 Ovarian Neoplasms 23 Neoplasms 23 Neoplasm Metastasis 23 Pancreatic Neoplasms 22 Head and Neck Neoplasms 18 Liver Neoplasms 17 Melanoma 15 Carcinoma, Renal Cell 15 Recurrence 13 Carcinoma 13 Stomach Neoplasms 12 Prostatic Neoplasms 12 Esophageal Neoplasms 11 Endometrial Neoplasms 11 Uterine Cervical Neoplasms 10 Carcinoma, Transitional Cell 10 Gallbladder Neoplasms 9 Esophageal Squamous Cell Carcinoma 8 Diabetes Mellitus, Insulin-Dependent, 12 8

Interventions

Drug Therapy 2 tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡